Navigation Links
Lexicon Pharmaceuticals to Present at Bio InvestorForum
Date:10/4/2007

THE WOODLANDS, Texas, Oct. 4 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the BIO InvestorForum at The Palace Hotel in San Francisco, California on Thursday, October 11, 2007 at 11:00 a.m. Pacific Time.

A live webcast of Lexicon's presentation may be accessed on its corporate website at http://www.lexpharma.com. An archived version of the webcast will be available on the website through October 19, 2007.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences , the leading ... healthcare industries, is pleased to announce Holger Braemer as Vice President of ... GmbH” based in Germany. , Braemer is an integral part of USDM’s expansion ...
(Date:4/20/2017)... , April 20, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: ... results at the International Liver Congress ("ILC") 2017 of the ... Amsterdam on the positive effects of ... model of obesity and metabolic syndrome. ... According to Dr. Lyne Gagnon, Vice-President of R&D ...
(Date:4/20/2017)... Minneapolis, MN and Bethesda, MD (PRWEB) , ... ... ... for Advancing Innovation announce the formation of a unique intellectual property (IP) sharing ... commercialization potential of their most promising inventions. A main component of this effort ...
(Date:4/20/2017)... -- For today, Stock-Callers.com redirects investors, attention to ... clinical research aimed at treating diseases and medical conditions. Under ... Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM ... our complimentary research reports on these stocks now at: ... http://stock-callers.com/registration ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/29/2017)... -- higi, the health IT company that operates the largest ... , today announced a Series B investment from BlueCross ... new investment and acquisition accelerates higi,s strategy to create ... health activities through the collection and workflow integration of ... and secures data today on behalf of over 36 ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
Breaking Biology News(10 mins):